>>Description of the research protocol "REACH AS"

Defining which remission criterion at Month 6 predicts remission at Month 12 in a real life clinical practice, in a cohort of ankylosing spondylitis patiens treated with etanercept (Enbrel)
Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Spondilarthrite A
Brugmann identifier : REACH AS
EudraCT identifier : B707201421295
ClinicalTrials.gov identifier : NCT02202850


Involved department : Rheumatology
Principal investigator : Bentin
Sponsor : Pfizer
Contact : Clinical Research Unit

>This protocol was approved by the CHU Liège ethics committee.